The tariff classification of Telbivudine (CAS-3424-98-4), imported in bulk and tablet forms, from Germany and other countries
Issued May 15, 2006 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3004.90.9110, 2934.99.4700
Product description
“Telbivudine” is the non-proprietary (generic) name for an investigational new drug that, according to information found on the World Wide Web, is currently being evaluated in Phase III clinical trials, in the U.S. and abroad, for use in the treatment of hepatitis, chronic hepatitis B, and cirrhosis. You indicate in your letter that registration of the name “Sibivo™” (which is not owned by your client), for use as Telbivudine’s proprietary (brand) name, is pending. Pursuant to the General Notice entitled Guidance Concerning the Tariff Classification of Pharmaceutical Products Imported for Clinical Research, published in the Customs Bulletin, Volume 34, No. 21, dated May 24, 2000,
CBP rationale
the applicable subheading for Telbivudine, imported in bulk form, will be 2934.99.4700, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Other: Drugs. the applicable subheading for Telbivudine tablets (i.e., tablets containing Telbivudine as the active ingredient) will be 3004.90.9110, HTSUS, which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Anti-infective medicaments: Other.
Full text
NY M82336 May 15, 2006 CLA-2-29:RR:NC:2:238 M82336 CATEGORY: Classification TARIFF NO.: 2934.99.4700; 3004.90.9110 Herbert J. Lynch, Esq. Sullivan & Lynch, P.C. Inner Tech Park 56 Roland Street, Suite 303 Boston, MA 02129-1223 RE: The tariff classification of Telbivudine (CAS-3424-98-4), imported in bulk and tablet forms, from Germany and other countries Dear Mr. Lynch: In your letter dated May 5, 2006, on behalf of your client, Idenix Pharmaceuticals, Inc., you requested a tariff classification ruling. “Telbivudine” is the non-proprietary (generic) name for an investigational new drug that, according to information found on the World Wide Web, is currently being evaluated in Phase III clinical trials, in the U.S. and abroad, for use in the treatment of hepatitis, chronic hepatitis B, and cirrhosis. You indicate in your letter that registration of the name “Sibivo™” (which is not owned by your client), for use as Telbivudine’s proprietary (brand) name, is pending. Pursuant to the General Notice entitled Guidance Concerning the Tariff Classification of Pharmaceutical Products Imported for Clinical Research, published in the Customs Bulletin, Volume 34, No. 21, dated May 24, 2000, the applicable subheading for Telbivudine, imported in bulk form, will be 2934.99.4700, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Other: Drugs.” The rate of duty will be 3.7 percent ad valorem. Pursuant to the General Notice entitled Guidance Concerning the Tariff Classification of Pharmaceutical Products Imported for Clinical Research, published in the Customs Bulletin, Volume 34, No. 21, dated May 24, 2000, the applicable subheading for Telbivudine tablets (i.e., tablets containing Telbivudine as the active ingredient) will be 3004.90.9110, HTSUS, which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Anti-infective medicaments: Other.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at: www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Nitrofurantoin Monohydrate (CAS No. 17140-81-7) in bulk powder form, from Italy
The tariff classification of Articaine Hydrochloride (CAS No. 23964-57-0) in bulk form, from Belgium
The tariff classification of Trifluridine (CAS No. 70-00-8) in bulk powder form, from Italy
The tariff classification of Clobetasol Propionate Spray and Entecavir Tablets in dosage form, from India
The tariff classification of Temozolomide capsules and Metronidazole tablets in dosage form, from India
The tariff classification of Linezolid tablets and Trazodone Hydrochloride tablets in dosage form, from India
The tariff classification of Amantadine Hydrochloride capsules and Acamprosate Calcium delayed release capsules in dosage form, from Spain and India, respectively
The tariff classification of Voriconazole Tablets in dosage form, from India
The tariff classification of Tetrahydrouridine (CAS 18771-50-1) in bulk form, from China
The tariff classification of Voriconazole Tablets and Nateglinide Tablets in dosage form, from Malta and India, respectively
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →